ArticleFrontiers in immunology2025
Serum magnesium predictive value in hepatocellular carcinoma patients on first-line immunotherapy: a retrospective study.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Serum magnesium plays a critical role in modulating immune responses and enhancing anti-tumor immunity in cancer patients. However, its predictive significance in relation to progression-free survival (PFS) and disease control rate (DCR) among hepatocellular carcinoma (HCC) patients undergoing first-line immunotherapy remains uninvestigated. Methods: This retrospective study analyzed HCC patients treated with immune checkpoint inhibitors (ICIs) in a derivation cohort and an independent validation cohort. Patients were enrolled based on predefined inclusion criteria. The primary endpoint was to assess the association between baseline serum magnesium levels prior to immunotherapy initiation and the disease control rate. The optimal cut-off value of serum magnesium for predicting disease control was determined using receiver operating characteristic (ROC) curve analysis. PFS was evaluated using the Kaplan-Meier method. Results: A total of 110 hepatocellular carcinoma patients treated with ICIs were enrolled in the derivation cohort. The DCR was 78.18%. ROC analysis identified a baseline serum magnesium level ≥0.785 mmol/L as predictive of disease control, with a sensitivity of 89.4% and specificity of 87.5% (AUC 0.869). Patients with baseline Mg Conclusion: Elevated serum magnesium levels prior to first-line immunotherapy are associated with improved clinical outcomes in HCC. Serum magnesium demonstrates significant predictive value and could serve as a cost-effective, accessible biomarker for guiding immunotherapy strategies in HCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.